Cellex Store
Founded in 2002, Cellex Incorporated is a biotech company that develops technologies, instruments and assays for testing of human diseases and conditions, particularly for point-of-care (POC) professional healthcare settings. Li’s guidance, the Cellex team continues to advance diagnostics for global healthcare for the following conditions :. CELLEX®, ®, QFLU®, HELIOS®, QSARS™, QCOV™ and WE ARE IN THE BUSINESS OF SAVING LIVES™ are trademarks owned by CELLEX, INC.. The FDA EUA authorized Cellex qSARS-CoV-2 IgG/IgM Rapid Test is available to medical professionals. The Cellex qSARS-CoV-2 Antigen Rapid Test is available to medical professionals and organizations for research, screening and surveillance use only. Based in Morrisville, NC, the company maintains both a GMP manufacturing site in Suzhou, China (ISO 13485 certified, FDA QSR) and an exclusive manufacturing partner in Zhengzhou (Hunan Province). Founder James Li and the Cellex team had already created a lineage of more than 50 pioneering diagnostic test successes on multiple platforms (drug resistance, UTI, TB, MI and others) when the COVID-19 outbreak began. The assays such as the qFLU Combo Test, which use the homogeneous biochemiluminescence assay (HBA) technology, are covered by the U.S.
This company is:
Verified
CELLEX QSARS-COV-2 IgG/IgM RAPID TEST KIT
{"blocks": [{"key": "92i0j", "data": {}, "text": "The qSARS-CoV-2 IgG/IgM Rapid Test is an aid in the diagnosis of patients with suspected SARS-CoV-2 infection in conjunction with clinical presentation and the results of other laboratory tests. ", "type": "unstyled", "depth": 0, "entityRanges": [], "inlineStyleRanges": []}, {"key": "2csb7", "data": {}, "text": "Results from the qSARS-CoV-2 IgG/IgM Rapid Test should not be used as the sole basis for diagnosis. ", "type": "unstyled", "depth": 0, "entityRanges": [], "inlineStyleRanges": []}, {"key": "16dok", "data": {}, "text": "Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, to perform moderate and high complexity tests.Results are for the detection of SARS-CoC-2 antibodies. IgM antibodies to SARS-CoV-2 are generally detectable in bold several days after initial infection, although levels over the course of infection are not well characterized. IgG antibodies to SARS-CoV-2 become detectable later following infection. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities. A CLIA categorization of this device would be consistent with other serology lateral flow moderate complexity devices.", "type": "unstyled", "depth": 0, "entityRanges": [], "inlineStyleRanges": []}], "entityMap": {}}
View all products
Keywords
Industries
City: Durham
State: North Carolina
Country: United States
Where is Cellex, Inc. located?
The company Cellex, Inc. is located in Durham, North Carolina, United States. It's worth noting that the company may has more corporate locations
How many employees does Cellex, Inc. approximately have?
As of the latest available information Cellex, Inc. has around 11-50 employees worldwide.
When was Cellex, Inc. founded?
Cellex, Inc. was founded in 2003
In which industries does Cellex, Inc. mainly work?
The company Cellex, Inc. has it's main focus in the industries of Professional Services
Cellex
Italy
1-10 Employees
1995
Plexense
South Korea
1-10 Employees
2012
Cellex Battery Systems
India
11-50 Employees
2021
AccuBioTech Co. Ltd.
China
11-50 Employees
2004
LEX Diagnostics
United Kingdom
11-50 Employees
2020
Plexision
United States
1-10 Employees
2008
Cellecta
United States
11-50 Employees
2006
Cellgen Diagnostics
1-10 Employees
2012
Topics which have been searched by others and may be interesting for you: